JP2022514344A5 - - Google Patents

Info

Publication number
JP2022514344A5
JP2022514344A5 JP2021535539A JP2021535539A JP2022514344A5 JP 2022514344 A5 JP2022514344 A5 JP 2022514344A5 JP 2021535539 A JP2021535539 A JP 2021535539A JP 2021535539 A JP2021535539 A JP 2021535539A JP 2022514344 A5 JP2022514344 A5 JP 2022514344A5
Authority
JP
Japan
Prior art keywords
compound
mmol
formula
ethyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535539A
Other languages
English (en)
Japanese (ja)
Other versions
JP7494181B2 (ja
JP2022514344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067088 external-priority patent/WO2020132014A1/en
Publication of JP2022514344A publication Critical patent/JP2022514344A/ja
Publication of JP2022514344A5 publication Critical patent/JP2022514344A5/ja
Priority to JP2024083009A priority Critical patent/JP7724911B2/ja
Application granted granted Critical
Publication of JP7494181B2 publication Critical patent/JP7494181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535539A 2018-12-19 2019-12-18 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 Active JP7494181B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024083009A JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782298P 2018-12-19 2018-12-19
US62/782,298 2018-12-19
US201962879900P 2019-07-29 2019-07-29
US62/879,900 2019-07-29
PCT/US2019/067088 WO2020132014A1 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083009A Division JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Publications (3)

Publication Number Publication Date
JP2022514344A JP2022514344A (ja) 2022-02-10
JP2022514344A5 true JP2022514344A5 (cg-RX-API-DMAC7.html) 2023-01-20
JP7494181B2 JP7494181B2 (ja) 2024-06-03

Family

ID=71098067

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535539A Active JP7494181B2 (ja) 2018-12-19 2019-12-18 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法
JP2024083009A Active JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024083009A Active JP7724911B2 (ja) 2018-12-19 2024-05-22 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法

Country Status (29)

Country Link
US (4) US11149007B2 (cg-RX-API-DMAC7.html)
EP (2) EP3897636B1 (cg-RX-API-DMAC7.html)
JP (2) JP7494181B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250144505A (cg-RX-API-DMAC7.html)
CN (2) CN113453681B (cg-RX-API-DMAC7.html)
AU (1) AU2019403207B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011968A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124130A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001665A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007973A2 (cg-RX-API-DMAC7.html)
DK (1) DK3897636T3 (cg-RX-API-DMAC7.html)
ES (1) ES3009308T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897636T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250095T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070506T2 (cg-RX-API-DMAC7.html)
IL (1) IL284223B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897636T (cg-RX-API-DMAC7.html)
MX (1) MX2021007473A (cg-RX-API-DMAC7.html)
MY (1) MY205718A (cg-RX-API-DMAC7.html)
PE (1) PE20212247A1 (cg-RX-API-DMAC7.html)
PL (1) PL3897636T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897636T (cg-RX-API-DMAC7.html)
RS (1) RS66556B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106507RA (cg-RX-API-DMAC7.html)
SI (1) SI3897636T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500111T1 (cg-RX-API-DMAC7.html)
TW (1) TWI820276B (cg-RX-API-DMAC7.html)
WO (1) WO2020132014A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104200B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021011968A2 (pt) * 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
WO2022019597A1 (ko) * 2020-07-21 2022-01-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
AU2022240688B2 (en) * 2021-03-17 2024-07-11 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Furan fused ring-substituted glutarimide compound
EP4359404A4 (en) * 2021-06-25 2025-06-04 Celgene Corporation Cereblon-binding compounds, compositions thereof and methods of treatment therewith
KR20240026939A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20240026946A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
US20260174749A1 (en) * 2022-11-09 2026-06-25 Bristol-Myers Squibb Company Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6- dione compounds
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025235600A1 (en) * 2024-05-07 2025-11-13 Bristol-Myers Squibb Company Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds
WO2025235577A1 (en) * 2024-05-09 2025-11-13 Bristol-Myers Squibb Company Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (de) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
WO2007136640A2 (en) 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
WO2012119559A1 (en) 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
SI2894151T1 (sl) * 2012-09-04 2021-01-29 Shanghai Hengrui Pharmaceutical Co. Ltd. Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR102226587B1 (ko) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2557235C1 (ru) 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2018009694A1 (en) 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Thiohydantoin androgen receptor antagonists for the treatment of cancer
TWI739888B (zh) 2016-10-07 2021-09-21 美商陶氏農業科學公司 農藥組合物及方法
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
WO2018089736A1 (en) 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
RU2747260C2 (ru) 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN109422725A (zh) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 前列腺癌治疗药物
HUE064356T2 (hu) 2017-11-28 2024-03-28 Aarti Pharmalabs Ltd Eljárás enzalutamid elõállítására új intermedier felhasználásával
CN111163638B (zh) 2017-12-05 2023-07-25 美国陶氏益农公司 杀有害生物组合物和方法
AU2019276514B2 (en) 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN109651256A (zh) 2018-11-20 2019-04-19 上海健康医学院 一种式(viii)的恩杂鲁胺的制备方法
BR112021011968A2 (pt) * 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Similar Documents

Publication Publication Date Title
AU2015282127B2 (en) Method for producing fused heterocyclic compound
RU2664643C2 (ru) Способ получения n-[(3-аминооксетан-3-ил)метил]-2-(1,1-диоксо-3,5-дигидро-1,4-бензотиазепин-4ил)-6-метил-хиназолин-4-амина
TWI460166B (zh) 製備2-亞胺基-四氫噻唑-4-酮衍生物之新穎方法
JP2818958B2 (ja) 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
IL278533B2 (en) Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US20080064876A1 (en) Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CN103108869A (zh) 制备氨基苯甲酰基苯并呋喃衍生物的方法
EP2903614A2 (en) Novel compounds, their synthesis and their uses
RU2473538C2 (ru) СПОСОБ ПОЛУЧЕНИЯ (S)-(-)-2-(N-ПРОПИЛАМИНО)-5-МЕТОКСИТЕТРАЛИНА И (S)-(-)-2-(N-ПРОПИЛАМИНО)-5-ГИДРОКСИТЕТРАЛИНА, ИХ СОЛИ С N-(3,5-ДИНИТРОБЕНЗОИЛ)-α-ФЕНИЛГЛИЦИНОМ, СПОСОБ ПОЛУЧЕНИЯ (6S)-(-)-5,6,7,8-ТЕТРАГИДРО-6-[ПРОПИЛ(2-ТИЕНИЛ)ЭТИЛ]АМИНО-1-НАФТОЛА (РОТИГОТИНА) (ВАРИАНТЫ)
JP2018506541A (ja) Nep阻害剤を調製するための方法および中間体
JP7292517B2 (ja) オキセタン-2-イルメタンアミンの調製のためのプロセスおよび中間体
JPS62212354A (ja) 環状中間体を用いたフエノ−ルエ−テルの製法
DD298911A5 (de) Azetidine, ihre herstellung und verwendung als zwischenprodukte fuer die herstellung von biologisch wirksamen substanzen
KR101744046B1 (ko) 실로도신 합성에 유용한 중간체의 제조방법
JP5417384B2 (ja) 含ハロゲンカルバマート基とアシル基を有するエチレンジアミン誘導体の製造方法、及びそれらの製造中間体
KR101698124B1 (ko) 3-(메틸아미노)-3-((r)-피롤리딘-3-일)프로판니트릴 또는 이의 염의 제조방법
KR102719583B1 (ko) 테리플루노미드의 신규한 제조 공정
JP5204438B2 (ja) 含フッ素アミン化合物の製造方法
US10189804B2 (en) Method for producing dicarboxylic acid compound
EP2141156A1 (en) Process for Preparation of Citalopram and Enantiomers
US20250145579A1 (en) Process for manufacturing an lpxc analog
EA046640B1 (ru) Способ и промежуточное соединение для получения оксетан-2-илметанамина
WO2014132994A1 (ja) 含窒素複素環誘導体の製造方法およびその製造中間体
WO2025206106A1 (ja) 3-フェニルシクロヘキセノン化合物及びその誘導体の製造方法
KR20230032513A (ko) 카모스타트 메실산염의 제조방법